How would it not make sense? Gilead is severely lacking in oncology and BMS is rich in IO agents. Gilead is desperate for onco considering the Kite acquisition. Also BMS has better cardiac. Sure maybe some overlap in HIV/Hep C but nothing that can't be divested. Care to explain what homework I didn't do?
This is the first time both companies could benefit from joining up - as long as BMS leadship is let go
